North America Cardiovascular Therapeutic Drugs Market

The size of the North American Cardiovascular Therapeutic Drugs Market is estimated to be USD 52.73 billion in 2022 and is poised to reach USD 58.51 billion by 2027 growing at a CAGR of 2.1%. The past several decades have witnessed huge success in the development of effective drug therapies for common cardiovascular disease. These therapies have been widely used with the rising prevalence of cardiovascular diseases resulting in the increased market for cardiovascular therapeutics.

Cardiovascular therapeutic drugs are the prescribed drugs and medicines for the diseases that are related to the structure and function of the heart and blood vessels. Cardiovascular diseases are responsible for majority of the deaths globally and continues to cause health problems. These health problems mainly include heart failure, blood clots, coronary artery disease, high cholesterol and others.

While cardiovascular disorders remain the major cause of morbidity and mortality in the world, the therapeutic drugs market is driven by the increasing aging population, epidemic of general medical problems like obesity & diabetes and growth in the per capita medical spending. However, shrinking target population, rising cost of drug development are the major restraint faced by the market. And, despite the wide prevalence of the cardiovascular diseases, pipelines for drug development products have been stagnant for variety of reasons.

North America cardiovascular therapeutic drug market is categorised on the basis of disease and drug class. On the basis of disease, the market is classified as cardiac arrhythmias, Arteriosclerosis, acute coronary syndrome, Myocardial infarction, Coronary artery disease, Peripheral artery disease, thrombosis, hyperlipidaemia, hypertension, cardiac failure diseases and others. On the basis of drug class the market is categorised as monotherapies and combination drug classes. On the basis of geography of North America, the market is segmented into United States and Canada.

The leading companies in the cardiovascular therapeutic drugs market includes AstraZeneca, Bayer, boehringer ingelheim, Bristol-Myers Squibb (BMS), Johnson & Johnson, Merck, Novartis, Pfizer, Sanofi and Takeda.